These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 33583020)

  • 21. [Biological microchip for establishing the structure of fusion transcripts involving MLL in children with acute leukemia].
    Nasedkina TV; Ikonnikova AY; Tsaur GA; Karateeva AV; Ammour YI; Avdonina MA; Karachunskii AI; Zasedatelev AS
    Mol Biol (Mosk); 2016; 50(6):968-977. PubMed ID: 28064313
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The potential of clofarabine in MLL-rearranged infant acute lymphoblastic leukaemia.
    Stumpel DJ; Schneider P; Pieters R; Stam RW
    Eur J Cancer; 2015 Sep; 51(14):2008-21. PubMed ID: 26188848
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reciprocal ATP5L-KMT2A gene fusion in a paediatric B lymphoblastic leukaemia/lymphoma (B-ALL) patient.
    Gestrich CK; Sadri N; Sinno MG; Pateva I; Meyerson HJ
    Br J Haematol; 2020 Oct; 191(2):e61-e64. PubMed ID: 32729113
    [No Abstract]   [Full Text] [Related]  

  • 24. Subclonality and prenatal origin of RAS mutations in KMT2A (MLL)-rearranged infant acute lymphoblastic leukaemia.
    Emerenciano M; Barbosa Tda C; de Almeida Lopes B; Meyer C; Marschalek R; Pombo-de-Oliveira MS
    Br J Haematol; 2015 Jul; 170(2):268-71. PubMed ID: 25613690
    [No Abstract]   [Full Text] [Related]  

  • 25. Molecular analysis of infant acute lymphoblastic leukemia: MLL gene rearrangement and reverse transcriptase-polymerase chain reaction for t(4; 11)(q21; q23).
    Hilden JM; Frestedt JL; Moore RO; Heerema NA; Arthur DC; Reaman GH; Kersey JH
    Blood; 1995 Nov; 86(10):3876-82. PubMed ID: 7579356
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol.
    van der Linden MH; Valsecchi MG; De Lorenzo P; Möricke A; Janka G; Leblanc TM; Felice M; Biondi A; Campbell M; Hann I; Rubnitz JE; Stary J; Szczepanski T; Vora A; Ferster A; Hovi L; Silverman LB; Pieters R
    Blood; 2009 Oct; 114(18):3764-8. PubMed ID: 19657114
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Azacitidine successfully maintained the second remission in an infant with KMT2A-rearranged acute lymphoblastic leukemia who relapsed after unrelated cord blood transplantation.
    Chijimatsu I; Imanaka Y; Tomizawa D; Eguchi M; Nishimura S; Karakawa S; Miki M; Hamamoto K; Fujita N
    Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28675638
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial.
    Tomizawa D; Miyamura T; Imamura T; Watanabe T; Moriya Saito A; Ogawa A; Takahashi Y; Hirayama M; Taki T; Deguchi T; Hori T; Sanada M; Ohmori S; Haba M; Iguchi A; Arakawa Y; Koga Y; Manabe A; Horibe K; Ishii E; Koh K
    Blood; 2020 Oct; 136(16):1813-1823. PubMed ID: 32845001
    [TBL] [Abstract][Full Text] [Related]  

  • 29. KMT2A rearranged acute lymphoblastic leukaemia: Unravelling the genomic complexity and heterogeneity of this high-risk disease.
    Forgione MO; McClure BJ; Eadie LN; Yeung DT; White DL
    Cancer Lett; 2020 Jan; 469():410-418. PubMed ID: 31705930
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96.
    Eckert C; von Stackelberg A; Seeger K; Groeneveld TW; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Escherich G; Henze G
    Eur J Cancer; 2013 Apr; 49(6):1346-55. PubMed ID: 23265714
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Minimal residual disease monitoring and preemptive immunotherapies for frequent 11q23 rearranged acute leukemia after allogeneic hematopoietic stem cell transplantation.
    Liu J; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Cheng YF; Qin YZ; Liu KY; Huang XJ; Zhao XS; Mo XD
    Ann Hematol; 2021 May; 100(5):1267-1281. PubMed ID: 33712867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Detection of BCR/ABL, MLL/AF4 and TEL/AML1 hybrid genes and monitoring of minimal residual disease in pediatric patients with acute lymphoblastic leukemia].
    Trka J; Zuna J; Haskovec C; Brabencová A; Kalinová M; Muzíková K; Paukertová R; Hrusák O; Zemanová Z; Michalová K; Starý J
    Cas Lek Cesk; 1999 Jan; 138(1):12-7. PubMed ID: 10953429
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship between subtype-specific minimal residual disease level and long-term prognosis in children with acute lymphoblastic leukemia.
    Huang XT; Wang CJ; Gao C; Xue TL; Zhao ZJ; Wang TY; Wu MY; Cui L; Zhang RD; Li ZG
    Ann Hematol; 2024 Sep; 103(9):3657-3665. PubMed ID: 38494553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcome of recurrent or refractory acute lymphoblastic leukemia in infants with MLL gene rearrangements: A report from the Japan Infant Leukemia Study Group.
    Tomizawa D; Koh K; Hirayama M; Miyamura T; Hatanaka M; Saikawa Y; Ishii E
    Pediatr Blood Cancer; 2009 Jul; 52(7):808-13. PubMed ID: 19229974
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
    zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
    Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cryptic and atypical KMT2A-USP2 and KMT2A-USP8 rearrangements identified by mate pair sequencing in infant and childhood leukemia.
    Blackburn PR; Smadbeck JB; Znoyko I; Webley MR; Pitel BA; Vasmatzis G; Xu X; Greipp PT; Hoppman NL; Ketterling RP; Baughn LB; Lindsey KG; Schandl CA; Wolff DJ; Peterson JF
    Genes Chromosomes Cancer; 2020 Jul; 59(7):422-427. PubMed ID: 32196814
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prognostic factors for childhood acute non-mature B-lymphoblastic leukemia].
    Jiang H; Gu LJ; Xue HL; Tang JY; Chen J; Pan C; Chen J; Xu C; Dong L; Zhou M
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):290-4. PubMed ID: 18554450
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extramedullary relapse of
    Aldoss I; Song JY
    Blood; 2018 May; 131(22):2507. PubMed ID: 29853461
    [No Abstract]   [Full Text] [Related]  

  • 39. Genetic alterations and MRD refine risk assessment for KMT2A-rearranged B-cell precursor ALL in adults: a GRAALL study.
    Kim R; Bergugnat H; Pastoret C; Pasquier F; Raffoux E; Larcher L; Passet M; Grardel N; Delabesse E; Kubetzko S; Caye-Eude A; Meyer C; Marschalek R; Lafage-Pochitaloff M; Thiebaut-Bertrand A; Balsat M; Escoffre-Barbe M; Blum S; Baumann M; Banos A; Straetmans N; Gallego-Hernanz MP; Chalandon Y; Graux C; Soulier J; Leguay T; Hunault M; Huguet F; Lhéritier V; Dombret H; Boissel N; Clappier E
    Blood; 2023 Nov; 142(21):1806-1817. PubMed ID: 37595275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk-directed treatment of infant acute lymphoblastic leukaemia based on early assessment of MLL gene status: results of the Japan Infant Leukaemia Study (MLL96).
    Isoyama K; Eguchi M; Hibi S; Kinukawa N; Ohkawa H; Kawasaki H; Kosaka Y; Oda T; Oda M; Okamura T; Nishimura S; Hayashi Y; Mori T; Imaizumi M; Mizutani S; Tsukimoto I; Kamada N; Ishii E
    Br J Haematol; 2002 Sep; 118(4):999-1010. PubMed ID: 12199778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.